An observational, cohort study to assess the comparative effectiveness of GP2017 versus SB5 following a mandatory switch from original adalimumab
Latest Information Update: 05 May 2021
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 05 May 2021 New trial record
- 29 Apr 2021 Results published in the Annals of the Rheumatic Diseases